PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 140 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2014. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,261,248 | -17.0% | 479,511 | +11.4% | 0.00% | – |
| Q2 2023 | $1,518,987 | +8.5% | 430,308 | -5.0% | 0.00% | – |
| Q1 2023 | $1,400,095 | +142041.6% | 453,105 | +94.7% | 0.00% | – |
| Q4 2022 | $985 | -99.3% | 232,769 | +306.2% | 0.00% | – |
| Q3 2022 | $136,000 | -54.2% | 57,305 | +35.5% | 0.00% | – |
| Q3 2021 | $297,000 | +0.3% | 42,298 | +31.0% | 0.00% | – |
| Q2 2021 | $296,000 | -25.4% | 32,281 | +704.2% | 0.00% | – |
| Q4 2017 | $397,000 | -91.4% | 4,014 | -89.6% | 0.00% | -100.0% |
| Q3 2017 | $4,615,000 | +26.3% | 38,550 | +23.2% | 0.00% | 0.0% |
| Q2 2015 | $3,654,000 | -47.5% | 31,299 | +6.2% | 0.00% | -50.0% |
| Q1 2015 | $6,956,000 | +59.4% | 29,462 | +27.8% | 0.00% | +33.3% |
| Q4 2014 | $4,364,000 | +196.1% | 23,059 | +273.1% | 0.00% | +200.0% |
| Q3 2014 | $1,474,000 | +85.4% | 6,180 | -18.7% | 0.00% | 0.0% |
| Q1 2014 | $795,000 | – | 7,606 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| EcoR1 Capital, LLC | 2,536,156 | $21,405,000 | 2.24% |
| Palo Alto Investors LP | 1,396,163 | $11,784,000 | 0.99% |
| Camber Capital Management LP | 1,950,000 | $16,458,000 | 0.98% |
| TANG CAPITAL MANAGEMENT LLC | 800,000 | $6,752,000 | 0.95% |
| Capital Impact Advisors, LLC | 147,303 | $1,243,000 | 0.52% |
| Sofinnova Investments, Inc. | 638,026 | $5,385,000 | 0.50% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 963,212 | $8,130,000 | 0.26% |
| RICE HALL JAMES & ASSOCIATES, LLC | 466,482 | $3,937,000 | 0.22% |
| PDT Partners, LLC | 204,238 | $1,724,000 | 0.14% |
| Eversept Partners, LP | 58,251 | $491,638 | 0.12% |